LOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition").
Read MoreLOVELAND, Colo., Sept. 12, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities (the "Acquisition").
Read MoreBoulder, CO (March 8, 2022) — LightDeck Diagnostics, the company leveraging planar waveguide technology to deliver lab-quality diagnostics in minutes, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2022.
Read MoreThis overview video explains how Lightdeck’s technology works.
Read MoreLightDeck Diagnostics is reimaging diagnostic technology by developing simple, fast, laboratory-quality testing almost anywhere. Finalists for the award included Proov and OnKure.
Read MoreOur conversations with private company executives aid our understanding of emerging trends in the diagnostics sector. For this spotlight, we interviewed LightDeck CEO Nick Traggis to better understand the company’s highly differentiated diagnostic platform that provides results at the point of care.
Read MoreOn July 6, 2021, the Department of Defense (DOD), on behalf of and in coordination with the Department of Health and Human Services (HHS), awarded a $35.1 million contract to LightDeck Diagnostics to increase the production capacity of LightDeck’s SARS-CoV-2 Ultra-Rapid Antigen and COVID-19 Total Antibody Tests.
Read MoreBill Whitaker reports on some of the innovations being developed to try to prevent the next pandemic. See the story Sunday on 60 Minutes.
LightDeck Diagnostics, a company formed earlier this year from the merger of startups mBio and Brava Diagnostics, has raised $11 million in funding for a new high-speed COVID-19 test, according to a statement.
Read More